Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIX1 shRNA
- Development stage
- Preclinical
- Lead developer
- Emory University
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
SIX1 shRNA is a short hairpin RNA designed to silence the expression of the SIX1 (Sine Oculis Homeobox Homolog 1) gene. SIX1 is a homeobox transcription factor that, when overexpressed, promotes cell proliferation, survival, and epithelial-mesenchymal transition (EMT) in various cancers, including T-cell acute lymphoblastic leukemia (T-ALL) and acute myeloid leukemia (AML). By targeting SIX1 mRNA for degradation via the RNA interference (RNAi) pathway, SIX1 shRNA reduces SIX1 protein levels, thereby impairing the proliferation and viability of leukemia cells, particularly those driven by the CALM-AF10 translocation. This approach is being investigated as a potential therapeutic strategy to disrupt the SIX1/EYA2 axis in hematologic malignancies.
- Other names
- shRNA targeting SIX1
02
Targets
SIX1 (Sine oculis homeobox homolog 1)
Beyond the preview
Go deeper on SIX1 shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIX1 shRNA.